CHF 4226 pMDI

DRUG2 trials

Sponsors

Chiesi Farmaceutici S.p.A.

Conditions

Chronic Obstructive Pulmonary Disease

Phase 1

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers

CompletedNCT00777595

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2008-10-31End: 2008-12-31Updated: 2009-03-27

Phase 2

Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00782535

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2008-12-31End: 2009-03-31Updated: 2019-11-06